Cephalosporins Should Be the Preferred Oral Antibiotics for Empiric Treatment of Outpatient Acute Pyelonephritis
When treating outpatient pyelonephritis empirically, consider prioritizing a cephalosporin over fluoroquinolones or TMP-SMX unless local resistance patterns strongly dictate otherwise. This shift aims to improve stewardship while maintaining adequate coverage for this common condition. Always confirm the choice with current institutional antibiograms.
This article addresses the ongoing challenge of selecting appropriate empiric oral antibiotics for managing acute pyelonephritis in the outpatient setting, a common and potentially serious ED presentation. While fluoroquinolones and TMP-SMX have historically been cited as first-line options according to various consensus guidelines, this review suggests a shift in preference toward cephalosporins. The core argument centers on optimizing antibiotic choice to ensure adequate clinical cure while simultaneously supporting robust antimicrobial stewardship efforts. Given the risk of complications like sepsis or renal injury, timely and correct empiric coverage is paramount for ED providers managing these patients.